Journals
Consult the user guide
For assistance, please contact us
Consult the user guide
For assistance, please contact us
Add search criteria
Results: 1 - 15 of 85
2015-06-19 [p.2851]
Q-1325 — Ms. Duncan (Etobicoke North) — With respect to the Action Plan for Women Entrepreneurs, identified in the 2015 Budget: (a) what consultations were undertaken for the development of the action plan; (b) for each consultation in (a), (i) what was the date, (ii) what was the location, (iii) what organizations and individuals were consulted, (iv) which briefings or submissions were included as part of the consultation process; (c) what are the specific components of the action plan; (d) for each specific component of the action plan, how much funding was allocated; (e) what is the development cost of the online platform to foster networking; (f) what is the advertising cost for the “Just One Pledge” campaign to encourage mentorship and championing, and what forms of advertising are being considered; (g) what is the process for identifying women who are looking for mentors, and for linking these women with mentors who have taken the “Just One Pledge”; (h) what follow-up and tracking will be undertaken to measure the success of the program, and when will the reporting of results take place; (i) what is the government's definition of an “enhanced” trade mission, and what funding will be provided for such a missions; (j) what is the selection process for companies led by women entrepreneurs for enhanced trade missions; (k) how many enhanced trade missions is the government planning to undertake, and, for each mission planned, (i) to what countries, (ii) what are the goals; (l) what will be the specific criteria required to access the Business Development Bank of Canada’s financing for women-owned businesses; (m) what consultations were undertaken to develop the criteria for financing, and for each consultation, what were the (i) dates, (ii) locations, (iii) organizations and individuals consulted; and (n) what is the timing for the national forum, (i) how many women are expected to participate, (ii) will financing be provided for travel and accommodation, (iii) what funding is being allocated for the forum? — Sessional Paper No. 8555-412-1325.
2015-06-18 [p.2835]
— by Ms. Duncan (Etobicoke North), six concerning climate change (Nos. 412-6129 to 412-6134);
2015-06-18 [p.2845]
— by Ms. Duncan (Etobicoke North), four concerning health care services (Nos. 412-6153 to 412-6156), two concerning foreign aid (Nos. 412-6157 and 412-6158), one concerning Old Age Security benefits (No. 412-6159), one concerning climate change (No. 412-6160), one concerning poverty (No. 412-6161), one concerning environmental assessment and review (No. 412-6162) and one concerning tobacco (No. 412-6163);
2015-06-12 [p.2747]
— by Ms. Duncan (Etobicoke North), three concerning health care services (Nos. 412-5956 to 412-5958);
2015-06-08 [p.2656]
— by Ms. Duncan (Etobicoke North), one concerning health care services (No. 412-5870);
2015-06-08 [p.2674]
— by Ms. Duncan (Etobicoke North), one concerning human rights (No. 412-5880), one concerning environmental assessment and review (No. 412-5881), one concerning the Canadian Charter of Rights and Freedoms (No. 412-5882) and one concerning natural gas (No. 412-5883);
2015-06-04 [p.2633]
Q-1155 — Ms. Duncan (Etobicoke North) — With respect to the Ebola vaccine developed at the National Microbiology Laboratory (NML): (a) on what date did research for the vaccine begin; (b) what are the names of the scientists involved in the research, and what are their positions; (c) why was the vaccine research initially undertaken; (d) was the research undertaken at any time in relation to anti-bioterrorism, and, if so, during what periods and with what specific mandate; (e) who provided funding for the research and development of the vaccine; (f) was the Government of Canada the only contributor to the research and development fund; (g) how much funding did the government provide, broken down by (i) percentage, (ii) department, (iii) date, (iv) dollar amount of contribution; (h) on what date was a robust immune response demonstrated to the vaccine; (i) on what date were research findings published and in what journal, and, if none were published, why not; (j) on what date was the vaccine patented and when was the initial patent application brought; (k) in which countries is the vaccine patented; (l) during what specific time period was the vaccine produced, (i) how many vials were produced, (ii) who was informed of this production, (iii) how were they informed; (m) was there a competitive process to sell the licensing rights or other entitlements relating to the vaccine; (n) if the process in (m) was created, (i) who developed the criteria for the licensing rights or other entitlements, broken down by position and department, (ii) what were the criteria to obtain the licensing rights or other entitlements, (iii) on what date was the competitive process launched, (iv) how many companies bid for the rights, (v) which companies bid for the rights and on what dates, (vi) how did NewLink Genetics (including Bioprotection Systems Corporation) meet the criteria for the licensing rights or other entitlements; (o) on what date was NewLink Genetics awarded the rights or entitlements; (p) what specific experience did NewLink Genetics have with vaccines, specifically when it comes to manufacturing capacity; (q) what NewLink Genetics products had reached the point of commercial production at the time of its bidding and purchase of the rights; (r) on what date did NewLink Genetics purchase the rights or entitlements from the Public Health Agency of Canada (PHAC), and for what cost; (s) as part of the licensing agreement, was NewLink Genetics expected to meet any milestones by any particular dates, (i) if so, when, (ii) if not, why not; (t) as part of the licensing agreement, what percentage royalties would NewLink Genetics pay Canada on any sales of the vaccine; (u) to date, how much income has the government obtained from licensing the vaccine, broken down by (i) up-front payments, (ii) milestone payments, (iii) any other payments; (v) did any of the NML or PHAC scientists/staff have any associations or links or monetary or proprietary interests or any other association with NewLink Genetics, and, if so, what are they; (w) did Canadian officials and the licensee meet annually in face-to-face meetings as required by Article 7.9 of the license agreement, and, if so, for all meetings, what is (i) the date, (ii) location, (iii) the names of all persons in attendance; (x) on what date did NewLink Genetics begin clinical trials of the vaccine; (y) how long was the delay between the onset of the commercial relationship with NewLink Genetics and start of clinical trials, broken down by (i) days, (ii) months, (iii) years; (z) what reason was given for the delay in (y); (aa) did the government question the progress of the clinical trials, if so, on what specific dates, and, if not, why not; (bb) in Canada's licensing agreement with NewLink Genetics, did Canada have the right to let other manufacturers make the vaccine for use in other countries "for compassionate care purposes" if NewLink had not received regulatory approval for the vaccine in the target country; (cc) did anyone in Canada urge the government to terminate its agreement with NewLink Genetics, and, if so, (i) who did so, (ii) on what dates, (iii) why; (dd) did anyone outside Canada request that Canada cancel NewLink's rights under the license, and, if so, (i) who did so, (ii) on what dates, (iii) why; (ee) did the government terminate the agreement, (i) if so, why, (ii) if not, why not; (ff) if the government terminated the agreement with NewLink Genetics, would Merck have paid the government the $30 million up front and $20 million once larger formal trials begun that went to NewLink Genetics, and would the government have been eligible to receive royalties on sales in certain markets; (gg) did the government approve of NewLink Genetics sub-licensing the vaccine to Merck; (hh) on what date did the government pay for IDT Biologika, to manufacture approximately 1 500 vials of the vaccine suitable for human trials, (i) how much was paid, (ii) was the Department of Defence involved, and, if so, why, (iii) did the Department of Defence contribute any funds; (ii) on what date did the Ebola outbreak begin in West Africa; (jj) on what date did the government reveal it had in storage an experimental vaccine that might be of use in combating the epidemic; (kk) on what date did the government offer vaccine to the World Health Organization (WHO); (ll) how many vials were sent to the WHO by the government, (i) on what date did the vials arrive, (ii) were there any delays; (mm) what are the results of the eight, phase l clinical trials in terms of (i) safety, (ii) immunogenic response, (iii) dose strength for phase 2/3 clinical trials; (nn) on what date did phase 2/3 clinical trials begin in Guinea, Liberia, and Sierra Leone; and (oo) what was the government’s involvement overall, broken down by (i) expertise, (ii) funding, (iii) personnel, (iv) other? — Sessional Paper No. 8555-412-1155.
2015-06-01 [p.2598]
— by Ms. Duncan (Etobicoke North), one concerning foreign aid (No. 412-5816);
2015-05-25 [p.2557]
— by Ms. Duncan (Etobicoke North), two concerning health care services (Nos. 412-5730 and 412-5731);
2015-05-13 [p.2529]
Q-1136 — Ms. Duncan (Etobicoke North) — With respect to Canada’s submission to the 20-year review on progress and challenges in implementing the Beijing Declaration and Platform for Action: (a) what specific consultations with provinces and territories did Status of Women Canada (SWC) undertake regarding Canada’s National Review, (i) on what dates did each consultation occur and with whom, (ii) what review process was put in place to ensure provinces and territories’ perspectives were adequately reflected; (b) who specifically drafted Canada’s National Review, (i) what departments gave specific input and on what dates, (ii) how many drafts of the submission were produced and on what dates, (iii) what departments and specific people reviewed each draft; (c) what Canadian NGOs were present at the NGO Forum before the United Nations Economic Commission of Europe Regional Review, and was there an opportunity to give feedback to SWC on the National Review, and, if so, what was the specific feedback; (d) what are the specific outstanding challenges the government acknowledges regarding the (i) pay gap, (ii) occupational segregation, (iii) violence against women and girls, (iv) participation of women in key leadership positions in Canadian business; (e) what specific annual investments has the government made between 2006 and the present to address each of the outstanding challenges identified in (d), and what legislative changes has the government passed to address these specified challenges; (f) what specific annual investments has the government made to reduce poverty since 2006 among (i) Aboriginal women, (ii) immigrant women, (iii) senior women, (iv) women with disabilities; (g) what legislative changes has the government passed to reduce poverty among (i) Aboriginal women, (ii) immigrant women, (iii) senior women, (iv) women with disabilities; (h) how is Canada a “leader in promoting gender equality”, including international rankings of Canada’s gender gap; (i) how did Canada “take seriously” its domestic commitments to achieve the goals of the Beijing Declaration and Platform for Action, and what are the specific annual investments made for each of the 12 priority themes for the years 2006 to the present; (j) how did Canada “take seriously” its international commitments to achieve the goals of the Beijing Declaration and Platform for Action; (k) what specific annual investment has the government made between 2006 and the present in (i) strengthening national systems to protect children and youth, especially girls, from violence, exploitation, and abuse, (ii) supporting safe and secure schools, (iii) providing opportunities for youth at-risk to find alternatives to crime and violence; (l) what information does the government possess concerning violence against women, specifically (i) what are the economic costs of spousal abuse in Canada, (ii) what percentage of survivors of spousal abuse are women, (iii) what specific annual investments has the government made to end violence against women and girls since 2006; (m) what specific annual investment has the government made in child advocacy centres across Canada since 2006; (n) what was the specific cost to create the new online resource centre “Stop Family Violence,” (i) how many hits has the resource had, (ii) how many times has it been used to create new programming or improve programming across the country; (o) what specific projects to assist women and girls fleeing domestic violence have been funded through the Homelessness Partnering Strategy, and what has been the investment in each project; (p) what specific projects has the government funded regarding emerging issues, specifically “violence committed in the name of honor”, and what was the amount invested; (q) what specific projects has the government funded regarding emerging issues, specifically “engagement of men and boys in violence prevention”, and what was the amount invested; (r) what was the specific cost to produce the “Stop Hating Online” resource, and how many hits has the site had; (s) what is the SWC’s annual investment in projects to end violence against women and girls between 2006 and the present; (t) what specific annual investments has the government made to prevent sexual violence between the years 2006 and the present; (u) how is Canada recognized as a leader in the protection of women’s rights with respect to (i) reproductive, (ii) maternal, (iii) newborn, (iv) child health; (v) what investment has the government made in the protection of women’s rights identified in (u) for the years 2006 to the present; (w) what are the specific target and indicators Canada is advocating for with respect to child marriage, early marriage, and forced marriage in the post-2015 development agenda; (x) what specific annual investments has Canada made with respect to First Nations and Inuit to improve health outcomes between 2006 and the present; and (y) how much money is set aside annually to ensure compliance with the “Health Portfolio Sex and Gender-Based Analysis Policy”? — Sessional Paper No. 8555-412-1136.
2015-05-08 [p.2507]
— by Ms. Duncan (Etobicoke North), one concerning health care services (No. 412-5606);
2015-05-08 [p.2508]
Q-1127 — Ms. Duncan (Etobicoke North) — With regard to international development assistance: what are the particulars of all grants, contributions, loans, or other financial assistance made by any department, agency, crown corporation, or other federal government organization, to any organization, body, or government, related to any project aimed at the development, promotion, or provision of sex education curriculum, services, products, or programming in any country other than Canada, since 2006, indicating in each case (i) the recipient, (ii) the amount of the financial assistance, (iii) the government organization providing the financial assistance, (iv) the program or policy pursuant to which the financial assistance was provided, (v) the location of the activity in respect of which the financial assistance was provided, (vi) the nature or description of the project, (vii) the file or reference number associated with the financial assistance? — Sessional Paper No. 8555-412-1127.
2015-05-06 [p.2482]
— by Ms. Duncan (Etobicoke North), one concerning crimes of violence (No. 412-5543);
Results: 1 - 15 of 85 | Page: 1 of 6

1
2
3
4
5
6
>
>|
Export As: XML CSV RSS

For more data options, please see Open Data